Key Highlights

  • Shares were up 12.37% to USD 9.45 in pre-market trading on November 3, 2026.
  • The stock fell 27.31% to close at USD 8.41 on November 2, 2026.
  • Third quarter results and a Business update are scheduled for November 3, 2026, with a call at 8:00 a.m. ET.
  • The company expects to complete its rolling FDA submission for COMP360 in the fourth quarter of 2026.
  • COMP360 holds FDA Breakthrough Therapy Designation for treatment-resistant depression and PTSD.

A Bounce After a Sharp Drop (up USD 1.04, 12.37%)

COMPASS Pathways (NASDAQ:CMPS) was up 12.37% to USD 9.45 in pre-market trading on November 3, 2026, measured against the November 2, 2026 close. That close was USD 8.41, after a decline of 27.31% on Monday from the October 30, 2026 close, with the shares trading between USD 7.54 and USD 11.76 during the session.

The Catalyst in Detail

On November 2, 2026, market reports said Usona Institute had submitted a Marketing application to the FDA for psilocybin in major depressive disorder. Reports tied Monday's decline in psychedelic developers to concern about competition in the race for a first approval. The company itself did not announce a reason for the drop.

The second Factor is the third quarter report. The company said it will release results for the quarter ended September 30, 2026, and a business update on November 3, 2026, with a conference call at 8:00 a.m. ET.

No company announcement explaining Monday's decline was identified, so the link to the competing filing rests on market commentary.

Business Background

COMPASS Pathways is a clinical-stage biotechnology company developing COMP360, an investigational synthetic psilocybin therapy. The company says it runs the largest classic psychedelic clinical program in treatment-resistant depression and is executing a late-stage PTSD trial.

In April 2026, the FDA granted rolling review and selected COMP360 for its Commissioner's National Priority Voucher pilot program. In August, the company said it expected to complete the submission in the fourth quarter of 2026. The treatment has not been approved.

The company also released a joint survey on treatment-resistant depression on November 2, 2026.

Balance Sheet and Risks

The company has no product revenue. Its prior quarter loss was USD 1.88 per share, according to reported figures, and consensus expectations for the third quarter had pointed to a smaller loss. The cash balance had not been disclosed in the sources reviewed, and the third quarter report should provide it.

Key risks include regulatory outcomes, competition from another psilocybin application, reimbursement and the availability of treatment centers. Biotech shares can move sharply on filings and on Earnings updates, and a pre-market rebound does not guarantee any follow-through.

What to Watch Next

Investors will focus on the November 3, 2026 results for cash runway, spending trends and any change to the timing of the FDA submission. Remarks on the call about the competitive filing may also matter.

Other items to follow include whether the stock holds its pre-market level after the opening bell, how Volume compares with Monday, and whether the company confirms its expected launch window.